Literature DB >> 31482335

How Transporters Have Changed Basic Pharmacokinetic Understanding.

Leslie Z Benet1, Christine M Bowman2, Jasleen K Sodhi2.   

Abstract

The emergence and continued evolution of the transporter field has caused re-evaluation and refinement of the original principles surrounding drug disposition. In this paper, we emphasize the impact that transporters can have on volume of distribution and how this can affect the other major pharmacokinetic parameters. When metabolic drug-drug interactions or pharmacogenomic variance changes the metabolism of a drug, the volume of distribution appears to be unchanged while clearance, bioavailability, and half-life are changed. When transporters are involved in the drug-drug interactions or pharmacogenomic variance, the volume of distribution can be markedly affected causing counterintuitive changes in half-life. Cases are examined where a volume of distribution change is significant enough that although clearance decreases, half-life decreases. Thus, drug dosing decisions must be made based on CL/F changes, not half-life changes, as such volume of distribution alterations will also influence the half-life results.

Entities:  

Keywords:  clearance; half-life; mean residence time; transporters; volume of distribution

Mesh:

Substances:

Year:  2019        PMID: 31482335      PMCID: PMC7241423          DOI: 10.1208/s12248-019-0373-3

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  21 in total

1.  The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.

Authors:  Eyal Sobol; Meir Bialer
Journal:  Biopharm Drug Dispos       Date:  2004-05       Impact factor: 1.627

2.  Predicting human hepatic clearance from in vitro drug metabolism and transport data: a scientific and pharmaceutical perspective for assessing drug-drug interactions.

Authors:  Gian Camenisch; Ken-ichi Umehara
Journal:  Biopharm Drug Dispos       Date:  2012-04-19       Impact factor: 1.627

3.  Organ clearance concepts: new perspectives on old principles.

Authors:  G L Sirianni; K S Pang
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

Review 4.  Model-based approaches to predict drug-drug interactions associated with hepatic uptake transporters: preclinical, clinical and beyond.

Authors:  Hugh A Barton; Yurong Lai; Theunis C Goosen; Hannah M Jones; Ayman F El-Kattan; James R Gosset; Jian Lin; Manthena V Varma
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-01-21       Impact factor: 4.481

5.  effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.

Authors:  Y Y Lau; Y Huang; L Frassetto; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2006-12-27       Impact factor: 6.875

6.  New Perspectives in Clinical Pharmacokinetics-1: the Importance of Updating the Teaching in Pharmacokinetics that both Clearance and Elimination Rate Constant Approaches Are Mathematically Proven Equally Valid.

Authors:  Roger Jelliffe; David Bayard
Journal:  AAPS J       Date:  2018-02-26       Impact factor: 4.009

Review 7.  Navigating Transporter Sciences in Pharmacokinetics Characterization Using the Extended Clearance Classification System.

Authors:  Ayman F El-Kattan; Manthena V S Varma
Journal:  Drug Metab Dispos       Date:  2018-03-01       Impact factor: 3.922

8.  Rosuvastatin Pharmacokinetics in Asian and White Subjects Wild Type for Both OATP1B1 and BCRP Under Control and Inhibited Conditions.

Authors:  Hsin-Fang Wu; Nadya Hristeva; Jae Chang; Xiaorong Liang; Ruina Li; Lynda Frassetto; Leslie Z Benet
Journal:  J Pharm Sci       Date:  2017-04-03       Impact factor: 3.534

9.  The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.

Authors:  J C Gorski; D R Jones; B D Haehner-Daniels; M A Hamman; E M O'Mara; S D Hall
Journal:  Clin Pharmacol Ther       Date:  1998-08       Impact factor: 6.875

10.  Transport vs. Metabolism: What Determines the Pharmacokinetics and Pharmacodynamics of Drugs? Insights From the Extended Clearance Model.

Authors:  G Patilea-Vrana; J D Unadkat
Journal:  Clin Pharmacol Ther       Date:  2016-08-27       Impact factor: 6.875

View more
  9 in total

Review 1.  Comparison of Canine and Human Physiological Factors: Understanding Interspecies Differences that Impact Drug Pharmacokinetics.

Authors:  Marilyn N Martinez; Jonathan P Mochel; Sibylle Neuhoff; Devendra Pade
Journal:  AAPS J       Date:  2021-04-27       Impact factor: 4.009

2.  A Simple Methodology to Differentiate Changes in Bioavailability From Changes in Clearance Following Oral Dosing of Metabolized Drugs.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  Clin Pharmacol Ther       Date:  2020-04-19       Impact factor: 6.875

3.  The Necessity of Using Changes in Absorption Time to Implicate Intestinal Transporter Involvement in Oral Drug-Drug Interactions.

Authors:  Jasleen K Sodhi; Leslie Z Benet
Journal:  AAPS J       Date:  2020-08-17       Impact factor: 4.009

4.  Challenging the Relevance of Unbound Tissue-to-Blood Partition Coefficient (Kpuu) on Prediction of Drug-Drug Interactions.

Authors:  Jasleen K Sodhi; Shuaibing Liu; Leslie Z Benet
Journal:  Pharm Res       Date:  2020-03-25       Impact factor: 4.200

5.  Intestinal Efflux Transporters P-gp and BCRP Are Not Clinically Relevant in Apixaban Disposition.

Authors:  Jasleen K Sodhi; Shuaibing Liu; Leslie Z Benet
Journal:  Pharm Res       Date:  2020-09-29       Impact factor: 4.200

6.  Recent developments in in vitro and in vivo models for improved translation of preclinical pharmacokinetics and pharmacodynamics data.

Authors:  Jaydeep Yadav; Mehdi El Hassani; Jasleen Sodhi; Volker M Lauschke; Jessica H Hartman; Laura E Russell
Journal:  Drug Metab Rev       Date:  2021-05-25       Impact factor: 6.984

7.  Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin.

Authors:  Chih-Hsuan Hsin; Marc S Stoffel; Malaz Gazzaz; Elke Schaeffeler; Matthias Schwab; Uwe Fuhr; Max Taubert
Journal:  Sci Rep       Date:  2020-07-27       Impact factor: 4.379

8.  Effect of Roxadustat on the Pharmacokinetics of Simvastatin, Rosuvastatin, and Atorvastatin in Healthy Subjects: Results From 3 Phase 1, Open-Label, 1-Sequence, Crossover Studies.

Authors:  Dorien Groenendaal-van de Meent; Martin den Adel; Virginie Kerbusch; Jan van Dijk; Tomohisa Shibata; Kota Kato; Marloes Schaddelee
Journal:  Clin Pharmacol Drug Dev       Date:  2022-02-19

9.  Volume of Distribution is Unaffected by Metabolic Drug-Drug Interactions.

Authors:  Jasleen K Sodhi; Caroline H Huang; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2021-02       Impact factor: 5.577

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.